Correlation Analysis of Hashimoto's Thyroiditis with Papillary Thyroid Carcinoma Occurrence and Its Central Lymph Node Metastasis: a Single Center Experience

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2025 Feb 21

PMID 39981137

Authors

Kang Sun

Xiaoming Wang

Dexuan Chen

Chaoqun Ma

Affiliations

Soon will be listed here.

Abstract

Purpose: This study investigates the clinicopathological characteristics of papillary thyroid carcinoma (PTC) with coexisting Hashimoto's thyroiditis (HT) and further explores the risk factors for central lymph node metastasis (CLNM) in PTC.

Method: A retrospective analysis was conducted on 415 PTC patients who underwent surgical treatment for thyroid cancer at the First Affiliated Hospital of Anhui University of Chinese Medicine from 2016 to 2022. Clinicopathological features were compared between PTC patients with and without HT. Univariate and multivariate logistic regression were used to analyze the risk factors of CLNM.

Result: The PTC+HT group had a higher proportion of female patients (85.5%) than the PTC group (P<0.05). Univariate analysis revealed no statistically significant difference between the two groups in eight aspects (all P>0.05). Multivariate analysis showed that HT was positively associated with the total number of central lymph node (CLN) dissected, Thyroid-stimulating hormone (TSH), Thyroid peroxidase antibody (TPOAb), and Thyroglobulin antibodies (TgAb), while identified as a protective factor against invasion with an odds ratio of 0.422 (95%CI 0.209-0.853, P=0.016). Through univariate and multivariate logistic regression, we proved that tumor position, Capsule + Extrathyroidal extension (ETE), multifocal tumors, and the total number of CLN dissected were independent risk factors for CLNM. Multiple linear regression analysis told us that invasion (β= 0.093, p=0.048) had a positively predictive impact on CLN positive rate.

Conclusion: Female PTC patients are more prone to concurrent HT, which elevates the levels of TSH, TPOAb, and TgAb. HT not only promotes the longitudinal growth of nodules and PTC development, but also reduces the risk of invasion and CLNM. Therefore, we posit that the impact of HT on PTC patients is a "double-edged sword". Isthmus, Capsule + ETE, multifocality, age < 55 years old, and male are high-risk factors for CLNM in PTC, while HT is regarded as a protective factor. Capsule + ETE is the primary risk factor affecting the CLN positive rate.

References

Ye Z, Gu D, Hu H, Zhou Y, Hu X, Zhang X . Hashimoto's thyroiditis, microcalcification and raised thyrotropin levels within normal range are associated with thyroid cancer. World J Surg Oncol. 2013; 11:56. PMC: 3717052. DOI: 10.1186/1477-7819-11-56. View

Rogler G . Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2013; 345(2):235-41. DOI: 10.1016/j.canlet.2013.07.032. View

Shen W, Pan X, Li Q . Utility and significance of clinical risk factor scoring model in predicting central compartment lymph node metastasis (CLNM) in patients with papillary thyroid cancer (PTC). Pak J Med Sci. 2022; 38(1):214-218. PMC: 8713228. DOI: 10.12669/pjms.38.1.4450. View

Danis N, Comlekci A, Yener S, Durak M, Calan M, Solmaz D . ASSOCIATION BETWEEN HASHIMOTO'S THYROIDITIS AND PAPILLARY THYROID CANCER: A SINGLE CENTER EXPERIENCE. Acta Endocrinol (Buchar). 2022; 18(1):74-78. PMC: 9365403. DOI: 10.4183/aeb.2022.74. View

Heo D, Won H, Tae K, Kang Y, Jeon E, Ji Y . Clinical impact of coexistent chronic lymphocytic thyroiditis on central lymph node metastasis in low- to intermediate-risk papillary thyroid carcinoma: The MASTER study. Surgery. 2024; 175(4):1049-1054. DOI: 10.1016/j.surg.2023.12.023. View

Rydzewska M, Jaromin M, Pasierowska I, Stozek K, Bossowski A . Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. Thyroid Res. 2018; 11:2. PMC: 5812228. DOI: 10.1186/s13044-018-0046-9. View

Maniakas A, Davies L, Zafereo M . Thyroid Disease Around the World. Otolaryngol Clin North Am. 2018; 51(3):631-642. DOI: 10.1016/j.otc.2018.01.014. View

Wang L, Chen J, Yuan X, Wang J, Sun L, Jiang J . Lymph node metastasis of papillary thyroid carcinoma in the context of Hashimoto's thyroiditis. BMC Endocr Disord. 2022; 22(1):12. PMC: 8734374. DOI: 10.1186/s12902-021-00923-2. View

Lim H, Devesa S, Sosa J, Check D, Kitahara C . Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017; 317(13):1338-1348. PMC: 8216772. DOI: 10.1001/jama.2017.2719. View

10.

Wang L, Li W, Ye H, Niu L . Impact of Hashimotoas thyroiditis on clinicopathologic features of papillary thyroid carcinoma associated with infiltration of tumor-infiltrating lymphocytes. Int J Clin Exp Pathol. 2020; 11(5):2768-2775. PMC: 6958247. View

11.

Tu T, Buhler S, Bartenschlager R . Chronic viral hepatitis and its association with liver cancer. Biol Chem. 2017; 398(8):817-837. DOI: 10.1515/hsz-2017-0118. View

12.

Divani S, Kalodimos G, Lioupis M, Ch Syrmos N . Hashimoto's thyroiditis and papillary thyroid carcinoma. Are cytokeratin 19 and P63 proteins of any diagnostic value?. Hell J Nucl Med. 2016; 19(3):250-253. DOI: 10.1967/s002449910408. View

13.

Sakiz D, Sencar M, Calapkulu M, Ozturk Unsal I, Aktas L, Ucan B . The Effects of Chronic Lymphocytic Thyroiditis on Clinicopathologic Factors in Papillary Thyroid Cancer. Endocr Pract. 2021; 27(12):1199-1204. DOI: 10.1016/j.eprac.2021.07.011. View

14.

Caturegli P, De Remigis A, Rose N . Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014; 13(4-5):391-7. DOI: 10.1016/j.autrev.2014.01.007. View

15.

Lin L, Li Z, Yan L, Liu Y, Yang H, Li H . Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019. J Hematol Oncol. 2021; 14(1):197. PMC: 8607714. DOI: 10.1186/s13045-021-01213-z. View

16.

Eaden J, Abrams K, Mayberry J . The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48(4):526-35. PMC: 1728259. DOI: 10.1136/gut.48.4.526. View

17.

Fiore E, Rago T, Latrofa F, Provenzale M, Piaggi P, Delitala A . Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer. 2011; 18(4):429-37. DOI: 10.1530/ERC-11-0028. View

18.

Tang Q, Pan W, Peng L . Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis. PLoS One. 2022; 17(6):e0269995. PMC: 9202927. DOI: 10.1371/journal.pone.0269995. View

19.

Levrero M, Zucman-Rossi J . Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016; 64(1 Suppl):S84-S101. DOI: 10.1016/j.jhep.2016.02.021. View

20.

Haddad R, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy N . Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(8):925-951. DOI: 10.6004/jnccn.2022.0040. View